Voyager Therapeutics, Inc. (VYGR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 171 | 37 | 41 | 250 | 80 | 40 | 34 | 20 |
| Operating profit | $m | -132 | -117 | ||||||
| Net profit | $m | 37 | -71 | -46 | 132 | -65 | -120 | -108 | -105 |
| EPS reported | $ | -2.04 | -1.81 | ||||||
| Operating cashflow per share | $ | -2.26 | -1.99 | ||||||
| Capex per share | $ | 0.04 | 0.01 | ||||||
| FCF per share | $ | -2.30 | -2.01 | ||||||
| Free cash flow | $m | -135 | -121 | ||||||
| Net debt | $m | -196 | -116 | ||||||
| Book value equity | $m | 196 | 154 | ||||||
| Book value per share | $ | 3.34 | 2.55 | ||||||
| Number of shares | m | 58.69 | 60.55 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.18 | 1.49 | ||||||
| P/S LTM | x | 5.71 | 6.69 | ||||||
| P/FCF LTM | x | -1.71 | -1.90 | ||||||
| EV/EBITDA LTM | x | -1.75 | -1.96 | ||||||
| EV/Sales LTM | x | 5.00 | 5.47 | ||||||
| Earnings Yield LTM | % | -51.90% | -56.04% | ||||||
| FCF Yield | % | -58.56% | -52.64% | ||||||
| Quality | |||||||||
| ROE | % | -61.06% | -57.92% | ||||||
| ROIC | % | -56.44% | -64.72% | ||||||
| Operating margin | % | -3.27% | -3.40% | ||||||
| Gross margin | % | -2.28% | -1.04% | ||||||
| FCF/Sales | % | -334.53% | -352.36% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -49.53% | -56.93% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -3.70 | -3.73 | ||||||
| Net Debt/EBITDA | x | 0.25 | 0.03 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +13.39% | ||||||
| Net debt/Equity | x | -1.00 | -0.75 | ||||||
| Gross debt/equity | x | 0.19 | 0.21 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Voyager Therapeutics, Inc. (VYGR)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free